Jci_page_head_homepage_01 Jci_page_head_homepage_02
Gregory J. Morton, James E. Blevins, Diana L. Williams, Kevin D. Niswender, Richard W. Gelling, Christopher J. Rhodes, Denis G. Baskin, Michael W. Schwartz
Published in Volume 115, Issue 3
J Clin Invest. 2005; 115(3):703–710 doi:10.1172/JCI22081
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

Effect of ARC-directed leptin receptor gene therapy on hindbrain c-Fos induction by CCK. Mean number of cFLI-positive nuclei per section in the AP (A) or NTS (B) as determined by immunohistochemistry after i.p. injection of either saline vehicle (white bars) or a 1.0-μg dose of CCK (black bars) 7 days after adenoviral microinjection of either Ad-GFP (in Fa/Fa or fak/fak rats) or Ad-LEPR-B–GFP (in fak/fak rats). *P < 0.05, vehicle vs. CCK; P < 0.05, CCK treatment in Fa/Fa Ad-GFP and fak/fak Ad-LEPR-B–GFP vs. fak/fak Ad-GFP–treated rats.